TABLE 1

The distribution of sample size by site and age group for assessment of immune response as part of Vi capsular polysaccharide vaccine effectiveness trials in Karachi and Kolkata

Blood sample collection no. and time periodAge group (yr)Sample sizes (n [%]) in:Total (n [%])
KarachiKolkata
ViHepAaTotalViHepATotalViHepATotal
1, day 0/prevaccination2–557 (46.7)47 (40.9)104 (43.9)3 (9.7)5 (15.6)8 (12.7)60 (39.2)52 (35.4)112 (37.3)
5–1665 (53.3)68 (59.1)133 (56.1)28 (90.3)27 (84.4)55 (87.3)93 (60.8)95 (64.6)188 (62.7)
2, 6 wk after vaccination2–540 (43.5)36 (39.6)76 (41.5)2 (6.5)3 (10.3)5 (8.3)42 (34.2)39 (32.5)81 (33.3)
5–1652 (56.5)55 (60.4)107 (58.5)29 (93.6)26 (89.7)55 (91.7)81 (65.9)81 (67.5)162 (66.7)
3, 2 yr after vaccination2–520 (43.5)17 (37.8)37 (40.7)1 (4.0)2 (8.7)3 (6.3)21 (29.6)19 (27.9)40 (28.8)
5–1626 (56.5)28 (62.2)54 (59.3)24 (96.0)21 (91.3)45 (93.8)50 (70.4)49 (72.1)99 (71.2)
All three samples2–519 (42.2)14 (34.2)33 (38.4)1 (4.2)2 (8.7)3 (6.4)20 (29.0)16 (25.0)36 (27.1)
5–1626 (57.8)27 (65.9)53 (61.6)23 (95.8)21 (91.3)44 (93.6)49 (71.0)48 (75.0)97 (72.9)
  • a HepA, hepatitis A vaccine.